The authors regret an error in the original paper wherein the number of patients with Diffuse Large B Cell Lymphoma (DLBCL) undergoing autologous hematopoietic cell transplantation in the U.S. in 2018 was incorrectly reported. Prior to 2018, the majority of DLBCL were collected under the category ‘NHL diffuse, large B-cell. To align data reporting with 2016 World Health Organization classification of lymphoid neoplasms, in 2018, the CIBMTR forms added new categories (including, DLBCL – germinal center B-cell type, DLBCL – activated B-cell type, and NHL with c-myc and bcl-2 and/or bcl6 rearrangements). We erroneously did not include these newly added subsets of DLBCL, resulting in the appearance of fewer patients undergoing autologous hematopoietic cell transplantation for DLBCL in 2018. Upon identification of this error, we have created an updated Figure 3 and updated the 3-year DLBCL survival outcomes after autologous and allogeneic hematopoietic cell transplantation in Table 2. The authors would like to apologise for any inconvenience caused.
Bibliographical notePublisher Copyright:
© 2021 The American Society for Transplantation and Cellular Therapy